Deukwoo Kwon

Abstract In epidemiologic studies, association estimates of an exposure with disease outcomes are often biased when the uncertainties of exposure are ignored. Consequently, corresponding confidence intervals (CIs) will not have correct coverage.

OBJECTIVE: Medication discrepancies between clinical systems may pose a patient safety hazard. In this paper, we identify challenges and quantify medication discrepancies across transitions of care. METHODS: We used structured clinical data and free-text hospital discharge summaries to compare active medications' lists at four time points: preadmission (outpatient), at-admission (inpatient), at-discharge (inpatient), and postdischarge (outpatient). Medication lists were normalized to RxNorm.

1. Introduction Prostate cancer is the most common cancer in American men. In 2022, more than a quarter of a million men was diagnosed with the disease [1]. Clinical decisions related to the choice of treatment, including active surveillance (AS), are multifactorial and complex. Prostate cancer risk assessment governs these decisions across a spectrum of local-regional diseases, from whether to biopsy to whether to intensify treatment using multimodality therapy.